Adicet Bio Q3 net loss $30.5M; ADI-001 trial expanded to six autoimmune indications

Adicet Bio, Inc.

2024-Q3 EPS reported -$1.02

Net loss of $30.5M ($0.34 per share) vs $49.9M ($1.16) in Q3 2023; cash $202.1M.
ADI-001 Phase 1 now covers LN, SLE, SSc, IIM, SPS, AAV; preliminary LN data expected 1H25.
FDA cleared IND amendment for ADI-001 in IIM and SPS in October 2024.
ADI-270 granted Fast Track for metastatic/advanced ccRCC; Phase 1 enrollment planned in Q4 2024.
Appointed Lloyd Klickstein, M.D., Ph.D. to Board of Directors in August 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.